
Biofrontera Inc. (NASDAQ: BFRIW) Stock Competitors & Peer Comparison
See BFRIW's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Pharmaceuticals Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for BFRIW and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BFRIW | $0.02 | -1.46% | 11.4M | -0.03 | -$0.60 | N/A |
| RPRX | $58.60 | -0.56% | 25.9B | 11.13 | $5.25 | +1.59% |
| CORT | $114.10 | -0.66% | 11.9B | 315.11 | $0.35 | N/A |
| WBA | $11.98 | +0.50% | 10.4B | -1.64 | -$7.29 | +4.17% |
| LQDA | $66.92 | -2.16% | 5.9B | 477.71 | $0.14 | N/A |
| KNSA | $77.76 | -1.98% | 5.9B | 85.82 | $0.90 | N/A |
| PBH | $46.85 | +0.82% | 2.1B | 10.17 | $4.42 | N/A |
| HROWL | $25.61 | +0.19% | 1.4B | N/A | N/A | N/A |
| LTGO | $21.69 | -9.35% | 1.4B | N/A | N/A | N/A |
| HROWM | $26.03 | -0.08% | 1.3B | N/A | N/A | N/A |
Stock Comparison
Royalty Pharma plc (NASDAQ: RPRX)
BFRIW vs RPRX Comparison September 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 11.4M. In comparison, RPRX has a market cap of 25.9B. Regarding current trading prices, BFRIW is priced at $0.02 on the NASDAQ, while RPRX trades at $58.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas RPRX's P/E ratio is 11.13. In terms of profitability, BFRIW's ROE is -1.28%, compared to RPRX's ROE of +0.12%. Regarding short-term risk, BFRIW is less volatile compared to RPRX. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check RPRX's competition here
Corcept Therapeutics Incorporated (NASDAQ: CORT)
BFRIW vs CORT Comparison September 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 11.4M. In comparison, CORT has a market cap of 11.9B. Regarding current trading prices, BFRIW is priced at $0.02 on the NASDAQ, while CORT trades at $114.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas CORT's P/E ratio is 315.11. In terms of profitability, BFRIW's ROE is -1.28%, compared to CORT's ROE of +0.08%. Regarding short-term risk, BFRIW is less volatile compared to CORT. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check CORT's competition here
Walgreens Boots Alliance, Inc. (NASDAQ: WBA)
BFRIW vs WBA Comparison September 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 11.4M. In comparison, WBA has a market cap of 10.4B. Regarding current trading prices, BFRIW is priced at $0.02 on the NASDAQ, while WBA trades at $11.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas WBA's P/E ratio is -1.64. In terms of profitability, BFRIW's ROE is -1.28%, compared to WBA's ROE of -0.57%. Regarding short-term risk, BFRIW is more volatile compared to WBA. This indicates higher risk in terms of short-term price fluctuations for BFRIW.Check WBA's competition here
Liquidia Corporation (NASDAQ: LQDA)
BFRIW vs LQDA Comparison September 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 11.4M. In comparison, LQDA has a market cap of 5.9B. Regarding current trading prices, BFRIW is priced at $0.02 on the NASDAQ, while LQDA trades at $66.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas LQDA's P/E ratio is 477.71. In terms of profitability, BFRIW's ROE is -1.28%, compared to LQDA's ROE of +1.50%. Regarding short-term risk, BFRIW is less volatile compared to LQDA. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check LQDA's competition here
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA)
BFRIW vs KNSA Comparison September 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 11.4M. In comparison, KNSA has a market cap of 5.9B. Regarding current trading prices, BFRIW is priced at $0.02 on the NASDAQ, while KNSA trades at $77.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas KNSA's P/E ratio is 85.82. In terms of profitability, BFRIW's ROE is -1.28%, compared to KNSA's ROE of +0.14%. Regarding short-term risk, BFRIW is less volatile compared to KNSA. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check KNSA's competition here
Prestige Consumer Healthcare Inc. (NYSE: PBH)
BFRIW vs PBH Comparison September 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 11.4M. In comparison, PBH has a market cap of 2.1B. Regarding current trading prices, BFRIW is priced at $0.02 on the NASDAQ, while PBH trades at $46.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas PBH's P/E ratio is 10.17. In terms of profitability, BFRIW's ROE is -1.28%, compared to PBH's ROE of +0.09%. Regarding short-term risk, BFRIW is less volatile compared to PBH. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check PBH's competition here
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL)
BFRIW vs HROWL Comparison September 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 11.4M. In comparison, HROWL has a market cap of 1.4B. Regarding current trading prices, BFRIW is priced at $0.02 on the NASDAQ, while HROWL trades at $25.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas HROWL's P/E ratio is N/A. In terms of profitability, BFRIW's ROE is -1.28%, compared to HROWL's ROE of -1.04%. Regarding short-term risk, BFRIW is more volatile compared to HROWL. This indicates higher risk in terms of short-term price fluctuations for BFRIW.Check HROWL's competition here
Latigo Biotherapeutics Inc. (NASDAQ: LTGO)
BFRIW vs LTGO Comparison September 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 11.4M. In comparison, LTGO has a market cap of 1.4B. Regarding current trading prices, BFRIW is priced at $0.02 on the NASDAQ, while LTGO trades at $21.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas LTGO's P/E ratio is N/A. In terms of profitability, BFRIW's ROE is -1.28%, compared to LTGO's ROE of N/A. Regarding short-term risk, BFRIW is less volatile compared to LTGO. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check LTGO's competition here
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM)
BFRIW vs HROWM Comparison September 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 11.4M. In comparison, HROWM has a market cap of 1.3B. Regarding current trading prices, BFRIW is priced at $0.02 on the NASDAQ, while HROWM trades at $26.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas HROWM's P/E ratio is N/A. In terms of profitability, BFRIW's ROE is -1.28%, compared to HROWM's ROE of -1.04%. Regarding short-term risk, BFRIW is more volatile compared to HROWM. This indicates higher risk in terms of short-term price fluctuations for BFRIW.Check HROWM's competition here
Cybin Inc. Common Stock (NASDAQ: HELP)
BFRIW vs HELP Comparison September 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 11.4M. In comparison, HELP has a market cap of 766.7M. Regarding current trading prices, BFRIW is priced at $0.02 on the NASDAQ, while HELP trades at $13.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas HELP's P/E ratio is -2.97. In terms of profitability, BFRIW's ROE is -1.28%, compared to HELP's ROE of -0.71%. Regarding short-term risk, BFRIW is less volatile compared to HELP. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check HELP's competition here
Sinovac Biotech Ltd. (NASDAQ: SVA)
BFRIW vs SVA Comparison September 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 11.4M. In comparison, SVA has a market cap of 464.9M. Regarding current trading prices, BFRIW is priced at $0.02 on the NASDAQ, while SVA trades at $6.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas SVA's P/E ratio is -5.68. In terms of profitability, BFRIW's ROE is -1.28%, compared to SVA's ROE of -0.01%. Regarding short-term risk, BFRIW is more volatile compared to SVA. This indicates higher risk in terms of short-term price fluctuations for BFRIW.Check SVA's competition here
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL)
BFRIW vs CUVL Comparison September 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 11.4M. In comparison, CUVL has a market cap of 297.5M. Regarding current trading prices, BFRIW is priced at $0.02 on the NASDAQ, while CUVL trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas CUVL's P/E ratio is N/A. In terms of profitability, BFRIW's ROE is -1.28%, compared to CUVL's ROE of N/A. Regarding short-term risk, BFRIW is less volatile compared to CUVL. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check CUVL's competition here
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI)
BFRIW vs CELG-RI Comparison September 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 11.4M. In comparison, CELG-RI has a market cap of 242.7M. Regarding current trading prices, BFRIW is priced at $0.02 on the NASDAQ, while CELG-RI trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, BFRIW's ROE is -1.28%, compared to CELG-RI's ROE of N/A. Regarding short-term risk, BFRIW is less volatile compared to CELG-RI. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check CELG-RI's competition here
High Tide Inc. (NASDAQ: HITI)
BFRIW vs HITI Comparison September 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 11.4M. In comparison, HITI has a market cap of 226.7M. Regarding current trading prices, BFRIW is priced at $0.02 on the NASDAQ, while HITI trades at $2.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas HITI's P/E ratio is -7.57. In terms of profitability, BFRIW's ROE is -1.28%, compared to HITI's ROE of -0.36%. Regarding short-term risk, BFRIW is less volatile compared to HITI. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check HITI's competition here
Citius Oncology, Inc. (NASDAQ: CTOR)
BFRIW vs CTOR Comparison September 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 11.4M. In comparison, CTOR has a market cap of 106M. Regarding current trading prices, BFRIW is priced at $0.02 on the NASDAQ, while CTOR trades at $1.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas CTOR's P/E ratio is -2.43. In terms of profitability, BFRIW's ROE is -1.28%, compared to CTOR's ROE of -1.03%. Regarding short-term risk, BFRIW is less volatile compared to CTOR. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check CTOR's competition here
Atlantic International Corp. (NASDAQ: ATLN)
BFRIW vs ATLN Comparison September 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 11.4M. In comparison, ATLN has a market cap of 73.2M. Regarding current trading prices, BFRIW is priced at $0.02 on the NASDAQ, while ATLN trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas ATLN's P/E ratio is -0.68. In terms of profitability, BFRIW's ROE is -1.28%, compared to ATLN's ROE of -83.20%. Regarding short-term risk, BFRIW is less volatile compared to ATLN. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check ATLN's competition here
Stablecoin Development Corp. (AMEX: SDEV)
BFRIW vs SDEV Comparison September 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 11.4M. In comparison, SDEV has a market cap of 52.2M. Regarding current trading prices, BFRIW is priced at $0.02 on the NASDAQ, while SDEV trades at $0.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas SDEV's P/E ratio is -0.18. In terms of profitability, BFRIW's ROE is -1.28%, compared to SDEV's ROE of +7.90%. Regarding short-term risk, BFRIW is less volatile compared to SDEV. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check SDEV's competition here
Rite Aid Corporation (NYSE: RAD)
BFRIW vs RAD Comparison September 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 11.4M. In comparison, RAD has a market cap of 36.8M. Regarding current trading prices, BFRIW is priced at $0.02 on the NASDAQ, while RAD trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas RAD's P/E ratio is -0.05. In terms of profitability, BFRIW's ROE is -1.28%, compared to RAD's ROE of +2.76%. Regarding short-term risk, BFRIW is less volatile compared to RAD. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check RAD's competition here
Damora Therapeutics, Inc. (NASDAQ: GLTO)
BFRIW vs GLTO Comparison September 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 11.4M. In comparison, GLTO has a market cap of 34.5M. Regarding current trading prices, BFRIW is priced at $0.02 on the NASDAQ, while GLTO trades at $21.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas GLTO's P/E ratio is -1.78. In terms of profitability, BFRIW's ROE is -1.28%, compared to GLTO's ROE of -0.83%. Regarding short-term risk, BFRIW is less volatile compared to GLTO. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check GLTO's competition here
Nasus Pharma Ltd. (AMEX: NSRX)
BFRIW vs NSRX Comparison September 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 11.4M. In comparison, NSRX has a market cap of 29.7M. Regarding current trading prices, BFRIW is priced at $0.02 on the NASDAQ, while NSRX trades at $3.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas NSRX's P/E ratio is -4.78. In terms of profitability, BFRIW's ROE is -1.28%, compared to NSRX's ROE of -1.59%. Regarding short-term risk, BFRIW is less volatile compared to NSRX. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check NSRX's competition here
SCYNEXIS, Inc. (NASDAQ: SCYX)
BFRIW vs SCYX Comparison September 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 11.4M. In comparison, SCYX has a market cap of 28M. Regarding current trading prices, BFRIW is priced at $0.02 on the NASDAQ, while SCYX trades at $4.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas SCYX's P/E ratio is -1.30. In terms of profitability, BFRIW's ROE is -1.28%, compared to SCYX's ROE of -0.21%. Regarding short-term risk, BFRIW is less volatile compared to SCYX. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check SCYX's competition here
Cosmos Health Inc. (NASDAQ: COSM)
BFRIW vs COSM Comparison September 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 11.4M. In comparison, COSM has a market cap of 17.9M. Regarding current trading prices, BFRIW is priced at $0.02 on the NASDAQ, while COSM trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas COSM's P/E ratio is -0.45. In terms of profitability, BFRIW's ROE is -1.28%, compared to COSM's ROE of -1.19%. Regarding short-term risk, BFRIW is less volatile compared to COSM. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check COSM's competition here
Biofrontera Inc. (NASDAQ: BFRI)
BFRIW vs BFRI Comparison September 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 11.4M. In comparison, BFRI has a market cap of 16.9M. Regarding current trading prices, BFRIW is priced at $0.02 on the NASDAQ, while BFRI trades at $1.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas BFRI's P/E ratio is -2.40. In terms of profitability, BFRIW's ROE is -1.28%, compared to BFRI's ROE of -1.28%. Regarding short-term risk, BFRIW is less volatile compared to BFRI. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check BFRI's competition here
Cerenome, Inc. (NASDAQ: CNSY)
BFRIW vs CNSY Comparison September 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 11.4M. In comparison, CNSY has a market cap of 14M. Regarding current trading prices, BFRIW is priced at $0.02 on the NASDAQ, while CNSY trades at $1.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas CNSY's P/E ratio is -0.48. In terms of profitability, BFRIW's ROE is -1.28%, compared to CNSY's ROE of -3.94%. Regarding short-term risk, BFRIW is less volatile compared to CNSY. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check CNSY's competition here
Scienture Holdings, Inc. (NASDAQ: SCNX)
BFRIW vs SCNX Comparison September 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 11.4M. In comparison, SCNX has a market cap of 12.7M. Regarding current trading prices, BFRIW is priced at $0.02 on the NASDAQ, while SCNX trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas SCNX's P/E ratio is -0.15. In terms of profitability, BFRIW's ROE is -1.28%, compared to SCNX's ROE of -0.54%. Regarding short-term risk, BFRIW is less volatile compared to SCNX. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check SCNX's competition here
China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD)
BFRIW vs CJJD Comparison September 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 11.4M. In comparison, CJJD has a market cap of 9.9M. Regarding current trading prices, BFRIW is priced at $0.02 on the NASDAQ, while CJJD trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas CJJD's P/E ratio is -0.46. In terms of profitability, BFRIW's ROE is -1.28%, compared to CJJD's ROE of -0.25%. Regarding short-term risk, BFRIW is less volatile compared to CJJD. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check CJJD's competition here
SunLink Health Systems, Inc. (AMEX: SSY)
BFRIW vs SSY Comparison September 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 11.4M. In comparison, SSY has a market cap of 7.9M. Regarding current trading prices, BFRIW is priced at $0.02 on the NASDAQ, while SSY trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas SSY's P/E ratio is -2.86. In terms of profitability, BFRIW's ROE is -1.28%, compared to SSY's ROE of -0.09%. Regarding short-term risk, BFRIW is less volatile compared to SSY. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check SSY's competition here
POMDOCTOR Ltd (NASDAQ: POM)
BFRIW vs POM Comparison September 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 11.4M. In comparison, POM has a market cap of 5.4M. Regarding current trading prices, BFRIW is priced at $0.02 on the NASDAQ, while POM trades at $0.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas POM's P/E ratio is -0.16. In terms of profitability, BFRIW's ROE is -1.28%, compared to POM's ROE of +0.16%. Regarding short-term risk, BFRIW is less volatile compared to POM. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check POM's competition here
Bio Green Med Solution, Inc. (NASDAQ: BGMS)
BFRIW vs BGMS Comparison September 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 11.4M. In comparison, BGMS has a market cap of 5.2M. Regarding current trading prices, BFRIW is priced at $0.02 on the NASDAQ, while BGMS trades at $0.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas BGMS's P/E ratio is -0.26. In terms of profitability, BFRIW's ROE is -1.28%, compared to BGMS's ROE of -0.32%. Regarding short-term risk, BFRIW is less volatile compared to BGMS. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check BGMS's competition here
Paranovus Entertainment Technology Ltd. (NASDAQ: PAVS)
BFRIW vs PAVS Comparison September 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 11.4M. In comparison, PAVS has a market cap of 3.5M. Regarding current trading prices, BFRIW is priced at $0.02 on the NASDAQ, while PAVS trades at $4.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas PAVS's P/E ratio is -0.05. In terms of profitability, BFRIW's ROE is -1.28%, compared to PAVS's ROE of -0.46%. Regarding short-term risk, BFRIW is less volatile compared to PAVS. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check PAVS's competition here
Eocene Ltd. (NASDAQ: EOCN)
BFRIW vs EOCN Comparison September 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 11.4M. In comparison, EOCN has a market cap of 3.5M. Regarding current trading prices, BFRIW is priced at $0.02 on the NASDAQ, while EOCN trades at $3.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas EOCN's P/E ratio is -0.24. In terms of profitability, BFRIW's ROE is -1.28%, compared to EOCN's ROE of N/A. Regarding short-term risk, BFRIW is less volatile compared to EOCN. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check EOCN's competition here
MedAvail Holdings, Inc. (NASDAQ: MDVL)
BFRIW vs MDVL Comparison September 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 11.4M. In comparison, MDVL has a market cap of 2.9M. Regarding current trading prices, BFRIW is priced at $0.02 on the NASDAQ, while MDVL trades at $1.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas MDVL's P/E ratio is -0.05. In terms of profitability, BFRIW's ROE is -1.28%, compared to MDVL's ROE of -2.39%. Regarding short-term risk, BFRIW is less volatile compared to MDVL. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check MDVL's competition here
ETHZilla Corporation Warrant (NASDAQ: ATNFW)
BFRIW vs ATNFW Comparison September 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 11.4M. In comparison, ATNFW has a market cap of 2.6M. Regarding current trading prices, BFRIW is priced at $0.02 on the NASDAQ, while ATNFW trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas ATNFW's P/E ratio is N/A. In terms of profitability, BFRIW's ROE is -1.28%, compared to ATNFW's ROE of -2.15%. Regarding short-term risk, BFRIW is less volatile compared to ATNFW. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check ATNFW's competition here
Bio Green Med Solution, Inc. (NASDAQ: BGMSP)
BFRIW vs BGMSP Comparison September 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 11.4M. In comparison, BGMSP has a market cap of 2.4M. Regarding current trading prices, BFRIW is priced at $0.02 on the NASDAQ, while BGMSP trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas BGMSP's P/E ratio is -0.84. In terms of profitability, BFRIW's ROE is -1.28%, compared to BGMSP's ROE of -0.32%. Regarding short-term risk, BFRIW is less volatile compared to BGMSP. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check BGMSP's competition here
AstraZeneca PLC ADRhedged (AMEX: AZNH)
BFRIW vs AZNH Comparison September 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 11.4M. In comparison, AZNH has a market cap of 1.6M. Regarding current trading prices, BFRIW is priced at $0.02 on the NASDAQ, while AZNH trades at $53.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas AZNH's P/E ratio is 38.35. In terms of profitability, BFRIW's ROE is -1.28%, compared to AZNH's ROE of +0.00%. Regarding short-term risk, BFRIW is more volatile compared to AZNH. This indicates higher risk in terms of short-term price fluctuations for BFRIW.Check AZNH's competition here
Leafly Holdings, Inc. (NASDAQ: LFLYW)
BFRIW vs LFLYW Comparison September 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 11.4M. In comparison, LFLYW has a market cap of 299.9K. Regarding current trading prices, BFRIW is priced at $0.02 on the NASDAQ, while LFLYW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas LFLYW's P/E ratio is -0.00. In terms of profitability, BFRIW's ROE is -1.28%, compared to LFLYW's ROE of +0.42%. Regarding short-term risk, BFRIW is more volatile compared to LFLYW. This indicates higher risk in terms of short-term price fluctuations for BFRIW.Check LFLYW's competition here
ProPhase Labs, Inc. (NASDAQ: PRPH)
BFRIW vs PRPH Comparison September 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 11.4M. In comparison, PRPH has a market cap of 175.2K. Regarding current trading prices, BFRIW is priced at $0.02 on the NASDAQ, while PRPH trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas PRPH's P/E ratio is N/A. In terms of profitability, BFRIW's ROE is -1.28%, compared to PRPH's ROE of -13.59%. Regarding short-term risk, BFRIW is less volatile compared to PRPH. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check PRPH's competition here
Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD)
BFRIW vs CPD Comparison September 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 11.4M. In comparison, CPD has a market cap of 0. Regarding current trading prices, BFRIW is priced at $0.02 on the NASDAQ, while CPD trades at $5.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas CPD's P/E ratio is N/A. In terms of profitability, BFRIW's ROE is -1.28%, compared to CPD's ROE of N/A. Regarding short-term risk, BFRIW is more volatile compared to CPD. This indicates higher risk in terms of short-term price fluctuations for BFRIW.Check CPD's competition here
Impax Laboratories, Inc. (NASDAQ: IPXL)
BFRIW vs IPXL Comparison September 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 11.4M. In comparison, IPXL has a market cap of 0. Regarding current trading prices, BFRIW is priced at $0.02 on the NASDAQ, while IPXL trades at $18.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas IPXL's P/E ratio is -10.11. In terms of profitability, BFRIW's ROE is -1.28%, compared to IPXL's ROE of -1.16%. Regarding short-term risk, BFRIW is less volatile compared to IPXL. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check IPXL's competition here
Express Scripts Holding Company (NASDAQ: ESRX)
BFRIW vs ESRX Comparison September 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 11.4M. In comparison, ESRX has a market cap of 0. Regarding current trading prices, BFRIW is priced at $0.02 on the NASDAQ, while ESRX trades at $92.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas ESRX's P/E ratio is 10.69. In terms of profitability, BFRIW's ROE is -1.28%, compared to ESRX's ROE of +0.26%. Regarding short-term risk, BFRIW is more volatile compared to ESRX. This indicates higher risk in terms of short-term price fluctuations for BFRIW.Check ESRX's competition here
Shire plc (NASDAQ: SHPG)
BFRIW vs SHPG Comparison September 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 11.4M. In comparison, SHPG has a market cap of 0. Regarding current trading prices, BFRIW is priced at $0.02 on the NASDAQ, while SHPG trades at $179.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas SHPG's P/E ratio is 11.35. In terms of profitability, BFRIW's ROE is -1.28%, compared to SHPG's ROE of +0.13%. Regarding short-term risk, BFRIW is more volatile compared to SHPG. This indicates higher risk in terms of short-term price fluctuations for BFRIW.Check SHPG's competition here
Orexigen Therapeutics, Inc. (NASDAQ: OREX)
BFRIW vs OREX Comparison September 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 11.4M. In comparison, OREX has a market cap of 0. Regarding current trading prices, BFRIW is priced at $0.02 on the NASDAQ, while OREX trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas OREX's P/E ratio is -0.14. In terms of profitability, BFRIW's ROE is -1.28%, compared to OREX's ROE of -0.54%. Regarding short-term risk, BFRIW is less volatile compared to OREX. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check OREX's competition here
POZEN Inc. (NASDAQ: POZN)
BFRIW vs POZN Comparison September 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 11.4M. In comparison, POZN has a market cap of 0. Regarding current trading prices, BFRIW is priced at $0.02 on the NASDAQ, while POZN trades at $5.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas POZN's P/E ratio is N/A. In terms of profitability, BFRIW's ROE is -1.28%, compared to POZN's ROE of +0.61%. Regarding short-term risk, BFRIW is less volatile compared to POZN. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check POZN's competition here